Global Radiotheranostics Market Size study & Forecast, by Radioisotope (Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, Others), by Approach (Targeted Therapeutic, Targeted Diagnostic), by Application (Oncology, Non Oncology) by and Regio

Global Radiotheranostics Market Size study & Forecast, by Radioisotope (Iodine-131, Iodine-123, Gallium-68, Lutetium-177, 18F with Y-90, Others), by Approach (Targeted Therapeutic, Targeted Diagnostic), by Application (Oncology, Non Oncology) by and Regional Analysis, 2023-2030

Global Radiotheranostics Market is valued at approximately USD 7.51 billion in 2022 and is anticipated to grow with a healthy growth rate of more than 13.49% over the forecast period 2023-2030. Radiotheranostics refers to the field of medicine that combine the therapeutic and diagnostic application of radiopharmaceuticals enabling personalized treatment strategies by using targeted radiation therapy and imaging techniques. The Radiotheranostics market is being driven by factors such as the Increasing prevalence of cancer cases and the rising adoption of injectable radiopharmaceuticals.

Radiotheranostics offers a personalized and targeted approach to cancer management. By combining diagnostic imaging with therapeutic interventions, it enhances precision, improves treatment outcomes, reduces side effects, and enables personalized therapies based on individual patients' characteristics and disease biology.According to the International Agency for Research on Cancer, Worldwide, an estimated 17 million new cancer cases in 2018 and it is estimated to rise by 27.5 million new cancer cases in 2040. Thus, rising in cancer cases fueling the market growth. In addition, increasing the approvals of new radiotheranostics agents and increasing public-private funding for research may create lucrative opportunities for the market. However, market expansion may hinder due to the high cost involved in research and development.

The key regions considered for the Global RadiotheranosticsMarket study includes Asia Pacific, North America, Europe, Latin America, and Middle East & Africa. North America holds the major share in radio theranostics market due to the rising overweight population and also rising adoption of large number of market players. Asia Pacific consider fastest growing market due to its large patient base and high investing nuclear medicine along with that rising orevlance of cancer.

Major market player included in this report are:
Novartis AG
Bayer AG
Progenics Pharmaceuticals, Inc.( Lantheus)
Telix Pharmaceuticals Limited.
ITM Isotope Technologies Munich SE
Life Molecular Imaging.
RadioMedix Inc.
IsoTherapeutics Group, LLC
Q BioMed Inc.
Nordic Nanovector ASA

Recent Developments in the Market:
• On May 2022, Transcode therapeutics Inc. announced the execution of an option agreement under which transcode will have the right to negotiate an exclusive, world, royalty-bearing licence for a radiotheranostic technology disclosed in patent application PCT/US2021/057912 Entitled THERAPEUTICS, RADIOLABLED NANOPARTICLES AND METHOD OF USE THEREOF.

• On Oct 2022, Clarity pharmaceuticals announced that the first patient in its phase1/2theranostic trial, which is testing 64Cu/67Cu SAR-bisPSMA theranostic product in people with metastatic castrate-restant prostate cancer, has been given a dose. The promising preclinical and clinical result so far support clarity’s investigation of the optimised SAR-bisPSMA product in additional oncology indications where the theranostic approach may be useful.

Global RadiotheranosticsMarket Report Scope:
Historical Data – 2020 - 2021
Base Year for Estimation – 2022
Forecast period - 2023-2030
Report Coverage - Revenue forecast, Company Ranking, Competitive Landscape, Growth factors, and Trends
Segments Covered – Radioisotope, Approach, Application, Region
Regional Scope - North America; Europe; Asia Pacific; Latin America; Middle East & Africa

The objective of the study is to define market sizes of different segments & countries in recent years and to forecast the values to the coming years. The report is designed to incorporate both qualitative and quantitative aspects of the industry within countries involved in the study.

The report also caters detailed information about the crucial aspects such as driving factors & challenges which will define the future growth of the market. Additionally, it also incorporates potential opportunities in micro markets for stakeholders to invest along with the detailed analysis of competitive landscape and product offerings of key players. The detailed segments and sub-segment of the market are explained below:

By Radioisotope:
Iodine-131
Iodine-123
Gallium-68
Lutetium-177
18F with Y-90
Others

By Approach:
Targeted Therapeutic
Targeted Diagnostic

Application:
Oncology
Non Oncology


By Region:

North America
U.S.
Canada

Europe
UK
Germany
France
Spain
Italy
ROE

Asia Pacific
China
India
Japan
Australia
South Korea
RoAPAC

Latin America
Brazil
Mexico

Middle East & Africa
Saudi Arabia
South Africa
Rest of Middle East & Africa

Companies Mentioned
Novartis AG
Bayer AG
Progenics Pharmaceuticals, Inc.( Lantheus)
Telix Pharmaceuticals Limited.
ITM Isotope Technologies Munich SE
Life Molecular Imaging.
RadioMedix Inc.
IsoTherapeutics Group, LLC
Q BioMed Inc.
Nordic Nanovector ASA

Please note:The single user license is non-downloadable and non-printable. Global Site license allows these actions.